Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553067/0/en/Vaxxinity-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html

Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients

VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates

Read more at globenewswire.com

Related news for (VAXX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.